Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party - Test2 - elhamkhani - TriplyDB

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

http://www.wikidata.org/entity/Q24648407

about

High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage Bacille-Calmette-Guerin non-responders: how to manage Management of carcinoma in situ of the bladder: best practice and recent developments Treatment options in non-muscle-invasive bladder cancer after BCG failure Current perspectives in bladder cancer management Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration The origins of urothelial carcinoma.Best practice in the treatment of nonmuscle invasive bladder cancer.CUA guidelines on the management of non-muscle invasive bladder cancer.Novel multisensor probe for monitoring bladder temperature during locoregional chemohyperthermia for nonmuscle-invasive bladder cancer: technical feasibility study.The management of BCG failure in non-muscle-invasive bladder cancer: an update.Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy.Intravesical therapies for bladder cancer - indications and limitations.Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.Current intravesical therapy for non-muscle invasive bladder cancer.The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.Hyperthermia for non-muscle invasive bladder cancer.Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer.Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations.Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer.Optimal timing of radical cystectomy in T1 high-grade bladder cancer.Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients.Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma of the Urinary Bladder: A Retrospective Multicentre Study Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

P2860

Q26739003-F52B79D7-212D-489F-B52D-BD724F1821AF Q26773679-8058BE9A-F3AC-4D5B-94A0-39F821A5E8CA Q26775772-7AD869E5-A83D-44E4-B570-AF6F18762C65 Q26775977-59AE675E-3C04-418D-8A18-99D4864FB5B0 Q26824914-943389E6-76D6-47C7-B5C2-7EB0143018D2 Q33665198-10798363-11C2-4BC8-BD30-908517AB4467 Q34121078-0BD0D388-3FC0-4DED-9679-60076C76A957 Q35688392-4D733C3C-8730-43DE-A306-3F9684299C97 Q36326208-20ECBA0E-D2DA-425D-8AFB-A982182A3B4F Q37406735-0125A744-2E66-49E7-B21C-65DFFF7194B1 Q37472576-DA420E94-CB9E-4164-82D0-54CCDA8FC0EF Q37872240-9C0B84BD-F3CF-4F74-9B38-B181CE02D6D5 Q38063552-62624CE8-247A-410F-8905-B3BFF8B0995A Q38075470-F8E73D8F-FCC6-4F78-BBDC-71E207883BD2 Q38129947-645E735E-E60B-446E-882B-6FEEB57CC6B5 Q38653106-1834C919-9AC5-4DC9-9448-97340292B4F5 Q38682106-52F877C3-DDE2-4228-932F-0DF81BC4B4E9 Q38711963-F6CF8928-D6D9-4D10-BD28-93FC83CADA2B Q38746589-E38C3F68-27E4-4B92-8562-328A9830B3A6 Q38801252-47BF1579-E15A-4177-8396-DC8FACF1F609 Q39005578-9873BBEC-31B7-4E57-87C2-6C808BFE1A0F Q39156389-633CAC57-37EB-4C53-B8AC-62303F0C81EB Q39197871-AD70186D-97C7-4FD5-9BD2-1ABB6FCAF1A2 Q39568939-86E280C2-FE3A-4355-B90D-9669F2A83974 Q39813009-0F7E2F34-50DA-4243-9CEB-E848A35CC772 Q41705995-85FF9F92-AD24-4D79-8AF0-65C4FE10A9E1 Q47109071-A92DC562-05E3-452E-95BA-E9605B1B1D22 Q58705075-6947AA47-C3D0-489F-95FB-96CBEF1E81EF Q58705101-F0261D5E-FEBE-4E4E-9B82-D824779D42B2

P2860

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

http://www.wikidata.org/entity/Q24648407

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Intravesical hyperthermia and ...... European Synergo working party

@ast

Intravesical hyperthermia and ...... European Synergo working party

@en

Intravesical hyperthermia and ...... European Synergo working party

@nl

type

label

Intravesical hyperthermia and ...... European Synergo working party

@ast

Intravesical hyperthermia and ...... European Synergo working party

@en

Intravesical hyperthermia and ...... European Synergo working party

@nl

prefLabel

Intravesical hyperthermia and ...... European Synergo working party

@ast

Intravesical hyperthermia and ...... European Synergo working party

@en

Intravesical hyperthermia and ...... European Synergo working party

@nl

P1433

Q24648407-CD25945E-BDEF-4E5C-BB93-46F3947B5695

P1476

Q24648407-C9760C7A-158E-49FD-974D-AB2F29EAF84D

P2093

Q24648407-4608D01F-936C-433F-B173-043695E04F21

Q24648407-6EBDB9A2-74A9-4ECD-9221-CC43539B5A15

Q24648407-85ABB8E3-0CB5-45EE-B454-B7F7B2E57A6F

Q24648407-91BB2C0F-3DB4-48DC-8A4D-66B566AFEAF2

Q24648407-A4E00068-B5DE-46FE-BC5F-BD8CA495E2A8

P2860

Q24648407-0BD938AD-68F2-4270-BB5B-22EFBD74E84B

Q24648407-3C9C8C06-1672-47C5-BF3A-78F1358F8A04

Q24648407-3E013DEE-28C4-4B2D-BA91-77D76C3359EB

Q24648407-46C371F0-D61F-4F1D-ABE1-6F8A09328DD7

Q24648407-5E005636-5213-4BD3-825E-AACC49B9982E

Q24648407-63ED8459-5DF5-491D-9E72-B2658E474682

Q24648407-7382607D-221A-4BFC-8065-5AEC82F4AD56

Q24648407-7A87377A-5DC8-468B-8F66-0857683FE8CD

Q24648407-AFA39E07-99BC-430F-A7C0-D7C3337097C0

Q24648407-B1CBEF00-BEC8-4906-ABEB-D91A2F33ABBA

P2888

Q24648407-C402AA9C-18C2-4BAA-890C-526BB4013CDC

P304

Q24648407-3581A49C-CA1C-4611-A9AC-A2AEAAFF5631

P31

Q24648407-49515BFC-D2ED-4CD9-B5B2-8F3F4DB7899E

P3181

Q24648407-E38E665C-A7F7-4C39-BAB7-06BEDC0307C5

P356

Q24648407-887BF38E-BFA7-48D1-B802-0A59DDB4676A

P407

Q24648407-A2BC1149-5465-423B-ADF1-F796873C7405

P433

Q24648407-2464BD06-9216-4DC0-BE2E-B2EFA848D22B

P478

Q24648407-161F1F1F-A4AA-4D62-8630-F3A3129CA2FA

P577

Q24648407-2559F7C3-9F54-4BE9-B8A2-3289780E7D70

P5875

Q24648407-D3256C8D-0033-4F0F-88B6-E512E2F63880

P6179

Q24648407-7058AC2B-D29A-49AF-9426-03E0A3D38BAC

P698

Q24648407-604A486B-B7EE-4531-986A-30B92AAA1233

P932

Q24648407-AC51D42D-B520-44EC-A371-87EC2EE93D8C

P3181

P356

S00345-009-0384-2

P1433

World Journal of Urology

P1476

Intravesical hyperthermia and ...... European Synergo working party

@en

P2093

J Alfred Witjes

http://www.w3.org/2001/XMLSchema#string

Kees Hendricksen

http://www.w3.org/2001/XMLSchema#string

O Gofrit

http://www.w3.org/2001/XMLSchema#string

O Nativ

http://www.w3.org/2001/XMLSchema#string

O Risi

http://www.w3.org/2001/XMLSchema#string

P2860

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study.

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.

Management of BCG failures in superficial bladder cancer: a review.

Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction.

EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer.

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.

The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group.

P2888

s00345-009-0384-2

P304

319-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3771636

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00345-009-0384-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24032637

http://www.w3.org/2001/XMLSchema#string

P6179

1014761375

http://www.w3.org/2001/XMLSchema#string

P698

19234857

http://www.w3.org/2001/XMLSchema#string

P932

2694311

http://www.w3.org/2001/XMLSchema#string